

# Haitang Yang

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6574264/publications.pdf>

Version: 2024-02-01

61  
papers

1,140  
citations

394421

19  
h-index

477307

29  
g-index

65  
all docs

65  
docs citations

65  
times ranked

1438  
citing authors

#	ARTICLE	IF	CITATIONS
1	Tumor-infiltrating lymphocytes are functionally inactivated by CD90+ stromal cells and reactivated by combined Ibrutinib and Rapamycin in human pleural mesothelioma. <i>Theranostics</i> , 2022, 12, 167-185.	10.0	6
2	Metabolic synthetic lethality by targeting NOP56 and mTOR in KRAS-mutant lung cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, 25.	8.6	6
3	Implementation of smoking signature as an improved biomarker predicting the response to immunotherapy. <i>Translational Lung Cancer Research</i> , 2022, 11, 124-125.	2.8	1
4	Functional and molecular characterization of PD1 <sup>+</sup> tumor-infiltrating lymphocytes from lung cancer patients. <i>Oncolmunology</i> , 2022, 11, 2019466.	4.6	4
5	Multi-scale integrative analyses identify THBS2 <sup>+</sup> cancer-associated fibroblasts as a key orchestrator promoting aggressiveness in early-stage lung adenocarcinoma. <i>Theranostics</i> , 2022, 12, 3104-3130.	10.0	23
6	Indocyanine green fluorescence-navigated thoracoscopy versus traditional inflation-deflation approach in precise uniportal segmentectomy: a short-term outcome comparative study. <i>Journal of Thoracic Disease</i> , 2022, 14, 741-748.	1.4	7
7	Comment on "Heterogeneity in PD-L1 expression in malignant peritoneal mesothelioma with systemic or intraperitoneal chemotherapy" <i>British Journal of Cancer</i> , 2021, 124, 1177-1178.	6.4	4
8	Four hub genes regulate tumor infiltration by immune cells, antitumor immunity in the tumor microenvironment, and survival outcomes in lung squamous cell carcinoma patients. <i>Aging</i> , 2021, 13, 3819-3842.	3.1	6
9	CD73, Tumor Plasticity and Immune Evasion in Solid Cancers. <i>Cancers</i> , 2021, 13, 177.	3.7	28
10	Preoperative peripheral blood neutrophil-to-lymphocyte ratios (NLR) and platelet-to-lymphocyte ratio (PLR) related nomograms predict the survival of patients with limited-stage small-cell lung cancer. <i>Translational Lung Cancer Research</i> , 2021, 10, 866-877.	2.8	31
11	CRISPR-Mediated Kinome Editing Prioritizes a Synergistic Combination Therapy for FGFR1-Amplified Lung Cancer. <i>Cancer Research</i> , 2021, 81, 3121-3133.	0.9	12
12	NF2 and Canonical Hippo-YAP Pathway Define Distinct Tumor Subsets Characterized by Different Immune Deficiency and Treatment Implications in Human Pleural Mesothelioma. <i>Cancers</i> , 2021, 13, 1561.	3.7	20
13	pN1 but not pN0/N2 predicts survival benefits of prophylactic cranial irradiation in small-cell lung cancer patients after surgery. <i>Annals of Translational Medicine</i> , 2021, 9, 562-562.	1.7	4
14	Targeting histone deacetylase enhances the therapeutic effect of Erastin-induced ferroptosis in EGFR-activating mutant lung adenocarcinoma. <i>Translational Lung Cancer Research</i> , 2021, 10, 1857-1872.	2.8	41
15	Chemotherapy-induced CDA expression renders resistant non-small cell lung cancer cells sensitive to 5'-deoxy-5-fluorocytidine (5'-DFCR). <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 138.	8.6	9
16	Malignant pleural mesothelioma co-opts BCL-XL and autophagy to escape apoptosis. <i>Cell Death and Disease</i> , 2021, 12, 406.	6.3	10
17	Surgical Resection of Primary Tumors Provides Survival Benefits for Lung Cancer Patients With Unexpected Pleural Dissemination. <i>Frontiers in Surgery</i> , 2021, 8, 679565.	1.4	1
18	Pharmaco-transcriptomic correlation analysis reveals novel responsive signatures to HDAC inhibitors and identifies Dasatinib as a synergistic interactor in small-cell lung cancer. <i>EBioMedicine</i> , 2021, 69, 103457.	6.1	20

#	ARTICLE	IF	CITATIONS
19	Synergistic effects of FGFR1 and PLK1 inhibitors target a metabolic liability in KRAS mutant cancer. <i>EMBO Molecular Medicine</i> , 2021, 13, e13193.	6.9	11
20	Smoking signature is superior to programmed death-ligand 1 expression in predicting pathological response to neoadjuvant immunotherapy in lung cancer patients. <i>Translational Lung Cancer Research</i> , 2021, 10, 3807-3822.	2.8	11
21	Improving Prediction Marker Models With the Ratio of CD39+CD8+ to Total CD8+ T cells: How Good Is Good Enough?. <i>Journal of Thoracic Oncology</i> , 2021, 16, e88-e91.	1.1	1
22	Peritumoral CD90+CD73+ cells possess immunosuppressive features in human non-small cell lung cancer. <i>EBioMedicine</i> , 2021, 73, 103664.	6.1	5
23	Neoadjuvant immunotherapy facilitates resection of surgically-challenging lung squamous cell cancer. <i>Journal of Thoracic Disease</i> , 2021, 13, 6816-6826.	1.4	6
24	Multicenter, prospective, observational study of a novel technique for preoperative pulmonary nodule localization. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2020, 160, 532-539.e2.	0.8	29
25	Therapeutic Landscape of Malignant Pleural Mesothelioma: Collateral Vulnerabilities and Evolutionary Dependencies in the Spotlight. <i>Frontiers in Oncology</i> , 2020, 10, 579464.	2.8	9
26	Beyond DNA Repair: DNA-PKcs in Tumor Metastasis, Metabolism and Immunity. <i>Cancers</i> , 2020, 12, 3389.	3.7	19
27	Biomarker-guided targeted and immunotherapies in malignant pleural mesothelioma. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592097142.	3.2	28
28	Co-Occurring LKB1 Deficiency Determinates the Susceptibility to ERK-Targeted Therapy in RAS-Mutant Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2020, 15, e58-59.	1.1	2
29	The Value of PD-L1 Expression in Metastatic Lymph Nodes of Advanced Non-Small Cell Lung Cancer. <i>Chest</i> , 2020, 158, 1785-1787.	0.8	4
30	Systematic Analysis of Aberrant Biochemical Networks and Potential Drug Vulnerabilities Induced by Tumor Suppressor Loss in Malignant Pleural Mesothelioma. <i>Cancers</i> , 2020, 12, 2310.	3.7	15
31	Pharmacotranscriptomic Analysis Reveals Novel Drugs and Gene Networks Regulating Ferroptosis in Cancer. <i>Cancers</i> , 2020, 12, 3273.	3.7	24
32	The Association of BAP1 Loss-of-Function With the Defect in Homologous Recombination Repair and Sensitivity to PARP-Targeted Therapy. <i>Journal of Thoracic Oncology</i> , 2020, 15, e88-e90.	1.1	12
33	Oncolytic Viral Therapy for Malignant Pleural Mesothelioma. <i>Journal of Thoracic Oncology</i> , 2020, 15, e111-e113.	1.1	5
34	CRISPR Screening Identifies WEE1 as a Combination Target for Standard Chemotherapy in Malignant Pleural Mesothelioma. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 661-672.	4.1	26
35	HSP90/AXL/eIF4E-regulated unfolded protein response as an acquired vulnerability in drug-resistant KRAS-mutant lung cancer. <i>Oncogenesis</i> , 2019, 8, 45.	4.9	38
36	Endoplasmic Reticulum Stress Signaling as a Therapeutic Target in Malignant Pleural Mesothelioma. <i>Cancers</i> , 2019, 11, 1502.	3.7	27

#	ARTICLE	IF	CITATIONS
37	New Horizons in KRAS-Mutant Lung Cancer: Dawn After Darkness. <i>Frontiers in Oncology</i> , 2019, 9, 953.	2.8	97
38	mTOR mediates a mechanism of resistance to chemotherapy and defines a rational combination strategy to treat KRAS-mutant lung cancer. <i>Oncogene</i> , 2019, 38, 622-636.	5.9	37
39	Analysis of unexpected small cell lung cancer following surgery as the primary treatment. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018, 144, 2441-2447.	2.5	17
40	Increased sensitivity to apoptosis upon endoplasmic reticulum stress-induced activation of the unfolded protein response in chemotherapy-resistant malignant pleural mesothelioma. <i>British Journal of Cancer</i> , 2018, 119, 65-75.	6.4	26
41	Surgical significance and efficacy of epidermal growth factor receptor tyrosine kinase inhibitors in patients with primary lung adenosquamous carcinoma. <i>Cancer Management and Research</i> , 2018, Volume 10, 2401-2407.	1.9	10
42	Prophylactic Cranial Irradiation for Patients with Surgically Resected Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2017, 12, 347-353.	1.1	50
43	Clinical outcomes of epidermal growth factor receptor tyrosine kinase inhibitors in recurrent adenosquamous carcinoma of the lung after resection. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 239-245.	2.0	18
44	Clinical outcomes of patients with metachronous second primary lung adenocarcinomas. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 295-302.	2.0	13
45	Clinical outcomes of surgically resected combined small cell lung cancer: a two-institutional experience. <i>Journal of Thoracic Disease</i> , 2017, 9, 151-158.	1.4	32
46	Reconstruction of mediastinal vessels for invasive thymoma: a retrospective analysis of 25 cases. <i>Journal of Thoracic Disease</i> , 2017, 9, 725-733.	1.4	25
47	Outcomes of patients with large cell neuroendocrine carcinoma of the lung after complete resection. <i>Translational Cancer Research</i> , 2017, 6, 483-492.	1.0	3
48	Survival prognostic factors for patients with synchronous brain oligometastatic non-small-cell lung carcinoma receiving local therapy. <i>OncoTargets and Therapy</i> , 2016, Volume 9, 4207-4213.	2.0	7
49	Single-stage bilateral pulmonary resections by video-assisted thoracic surgery for multiple small nodules. <i>Journal of Thoracic Disease</i> , 2016, 8, 469-475.	1.4	35
50	EGFR tyrosine kinase inhibitors versus chemotherapy as first-line therapy for non-small cell lung cancer patients with the L858R point mutation. <i>Scientific Reports</i> , 2016, 6, 36371.	3.3	6
51	Surgical Therapy for Bilateral Multiple Primary Lung Cancer. <i>Annals of Thoracic Surgery</i> , 2016, 101, 1145-1152.	1.3	51
52	Serum carbohydrate antigen 12-5 level enhances the prognostic value in primary adenosquamous carcinoma of the lung: a two-institutional experience. <i>Interactive Cardiovascular and Thoracic Surgery</i> , 2016, 22, 419-424.	1.1	3
53	EGFR tyrosine kinase inhibitor (TKI) in patients with advanced non-small cell lung cancer (NSCLC) harboring uncommon EGFR mutations: A real-world study in China. <i>Lung Cancer</i> , 2016, 96, 87-92.	2.0	81
54	Efficacy of EGFR tyrosine kinase inhibitors for non-adenocarcinoma lung cancer patients harboring EGFR-sensitizing mutations in China. <i>Journal of Cancer Research and Clinical Oncology</i> , 2016, 142, 1325-1330.	2.5	20

#	ARTICLE	IF	CITATIONS
55	Resected Tracheal Adenoid Cystic Carcinoma: Improvements in Outcome at a Single Institution. <i>Annals of Thoracic Surgery</i> , 2016, 101, 294-300.	1.3	38
56	Comparison of outcomes of tyrosine kinase inhibitor in first- or second-line therapy for advanced non-small-cell lung cancer patients with sensitive EGFR mutations. <i>Oncotarget</i> , 2016, 7, 68442-68448.	1.8	13
57	Clinical experience with titanium mesh in reconstruction of massive chest wall defects following oncological resection. <i>Journal of Thoracic Disease</i> , 2015, 7, 1227-34.	1.4	12
58	Clinical outcomes of surgery after induction treatment in patients with pathologically proven N2-positive stage III non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2015, 7, 1616-23.	1.4	10
59	Progress in various crosslinking modification for acellular matrix. <i>Chinese Medical Journal</i> , 2014, 127, 3156-64.	2.3	4
60	Responsive signatures established by pharmaco-transcriptomic correlation analysis identifies subsets for PARP-targeted therapy and reveals potential synergistic interactors. , 0, , .		0
61	Peritumoral CD90 <sup>+</sup>CD73 <sup>+</sup> Cells Possess Immunosuppressive Features in Human Non-Small Cell Lung Cancer. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0